Slide 1: Coloplast Earnings Conference Call 9M 2017/18
Coloplast Earnings Conference Call 9M 2017/18 8 August 2018
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: In Q3 Coloplast delivered 8% organic growth for the fifth consecutive quarter
In Q3 Coloplast delivered 8% organic growth for the fifth consecutive quarter Q3 Highlights Revenue growth +8% • Q3 organic growth of 8% (8% reported growth in DKK(1)) Reported revenue (DKKm) +6% • Negative FX impact from USD/DKK and ARS/DKK. Acquisitions Organic growth contributed 1% to growth 11,5
Slide 4: 8% organic growth in 9M driven by strong performance across business areas
8% organic growth in 9M driven by strong performance across business areas 9M 17/18 revenue by business area 9M 17/18 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm growth Ostomy Ca
Slide 5: 9M 17/18 reported revenue driven by strong organic growth but significantly impacted by FX
9M 17/18 reported revenue driven by strong organic growth but significantly impacted by FX Comments Revenue development • 9M 2017/18 reported revenue increased by DKK 667m (DKKm) 135 or 6% compared to 9M 2016/17 -478 12,215 • The majority of growth was driven by organic growth 920 contributing DKK 9
Slide 6: 9M EBIT margin dilution due to increased commercial investments across business areas and regions
9M EBIT margin dilution due to increased commercial investments across business areas and regions Comments EBIT margin development (%) • EBIT fell 1% to DKK 3,676m with a reported margin of 30% (31% in constant currencies) compared to 32% last year 32.1 • Gross margin of 67% compared to 68% same per
Slide 7: Upgraded organic growth guidance for FY 2017/18
Upgraded organic growth guidance for FY 2017/18 Guidance 2017/18 Guidance 2017/18 (DKK)* Key assumptions • Limited impact from patent expiry ~8% from 7-8% Unchanged at ~6% • Up to 1% negative price pressure of which up to DKK 100m from Sales growth price reform in Greece (organic) • DKK guidance inc
Slide 8: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast A/S - Ostomy Care / C